Compare Gilead Sciences, Inc. (GILD) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs ON Holding AG — how do they compare? Gilead Sciences, Inc. trades at $133.06 (market cap $163.51B), while ON Holding AG trades at $38.67 (market cap $12.49B). The key difference: Gilead Sciences, Inc. is far larger — about 13.1× ON Holding AG's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while ON Holding AG pays none. Which is the better fit depends on your goals.
| GILD | ONON | |
|---|---|---|
Market Cap | $163.51B | $12.49B |
Sector | Health | Technology |
52-Week High | $155.80 | $54.24 |
52-Week Low | $108.22 | $31.88 |
Enterprise Value | $178.05B | $11.81B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
ONON trades at $37.80, up 0.16% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $0.47 versus $0.34, revenue of $3.01B in 2025, and improving margins. Analyst sentiment is bullish with 77% buy ratings and a $47.33 consensus price target, suggesting 25% upside. Recent news highlights innovation and expansion into luxury lifestyle markets.
Outlook remains positive driven by earnings momentum and margin expansion, but risks include premium valuation and competitive pressures. The stock offers growth potential if execution continues, though high P/E of 40.42 requires sustained profit growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
